Skip to content
Medical Learning Institute Inc
Home
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
Menu Toggle
About MLI Accreditation
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Medical Learning Institute Inc
Main Menu
Home
Activities
Menu Toggle
Upcoming Events
On-Demand Activities
Educational Series
Menu Toggle
Featured Educational Series
Menu Toggle
Oncology Communications Skills
Shedding Light on T2D
The Evolution of HCT: NMPD Series
Vaccines in Older Adults Series
Accreditation
Menu Toggle
About MLI Accreditation
About Us
Menu Toggle
About MLI
Societies and Partners
CE Coordinator Incentive Program (CECIP)
Contact Us
Post-Assessment
Please enable JavaScript in your browser to complete this form.
Please enable JavaScript in your browser to complete this form.
Name
*
First
Last
Email
*
NPI Number
Profession
Physician
Physicians Associate
Nurse Practitioner
Other
the a best
Primary Specialty
Family medicine/primary care
Other
Please select your location
Nevada
South Dakota
Alaska
Georgia
Utah
Indiana
Mississippi
Louisiana
Pennsylvania
Missouri
Did you previously participate in the online, enduring activity, “Overcoming Obesity: A PCP’s Guide to Comprehensive Obesity Care”?
Yes
No
1. According to the 2023 Consensus Statement on Obesity, which best describes BMI's role in diagnosing obesity?
A. BMI should be used in all clinical settings due to consistent classification cutoffs
B. BMI should be complemented by other clinical assessments and patient factors
C. BMI has been replaced by more modern metrics (eg waist-to-height ratio) as the primary diagnostic tool
D. BMI is a measurement of body fat for screening obesity and related comorbidities
2. You are assessing a patient with a BMI of 34 and mild complications. According to the latest AACE/ACE framework, what is the correct obesity staging assessment for this patient?
A. Overweight
B. Obesity Stage 1
C. Obesity Stage 2
D. Obesity Stage 3
3. Your patient’s weight changed from 220 to 185 pounds, but he is now struggling to adhere to his treatment plan. What barrier might be affecting his weight loss?
A. Weight discrimination from healthcare practitioners
B. Increased thermic effect of feeding
C. Decreased resting metabolic rate
D. Increased active energy expenditure
4. Which two obesity drugs have shown the greatest weight reduction in trials (~10-16% and ~15-21%)?
A. Phentermine/topiramate-ER and tirzepatide
B. Semaglutide and tirzepatide
C. Liraglutide and semaglutide
D. Orlistat and naltrexone
5. Which strategy best supports patients with larger bodies in the healthcare setting?
A. Ask patients at check-in what size blood pressure cuff they’d prefer
B. Incorporate bariatric chairs and reinforced exam tables
C. Ensure medical devices are in a central, accessible location
D. Provide weight loss success stories among waiting room reading material
6. After examining a patient with a BMI of 34 and suspected T2D, what is the most appropriate way to record your findings?
A. "Patient may be diabetic."
B. "Patient with obesity was counseled on risks of T2D."
C. "Obese patient presents with T2D symptoms."
D. "Overweight patient may also have diabetes.”
7. What tools are needed for PCPs to successfully support their patients in long-term weight management goals?
8. What is the greatest barrier to initiating patient conversations about weight?
Submit
Scroll to Top
